Data for Alimta and Cyramza plus keytruda in NSCLC presented at ASCO
Clinical study data from two of Lilly’s ongoing immuno-oncology clinical collaborations with Merck (known as MSD outside the US and Canada) have been presented at ASCO.
Click on this link for more information.
